Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib

Matthew D. Hellmann, Boris Reva, Helena Yu, Valerie W. Rusch, Naiyer A. Rizvi, Mark G. Kris, Maria E. Arcila

Research output: Contribution to journalArticlepeer-review

24 Scopus citations
Original languageEnglish
Pages (from-to)e73-e74
JournalJournal of Thoracic Oncology
Issue number10
StatePublished - 1 Oct 2014
Externally publishedYes

Cite this